Clinical Study
Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
Table 1
Patient’s characteristics.
| | Group A () | Group B () |
| Age | | | Median (range) (years) | 49 (28–73) | 48 (28–73) |
| FIGO stage | | | Ia : Ib: IIa | 4 : 78 : 27 | 7 : 67 : 27 |
| Histology | | | Squamous : nonsquamous | 86 : 23 | 101 : 0 |
| Serum SCC antigen | | | Missing | 2 | 4 | Median (Range) (ng/mL) | 1.40 (0.1–29.2) | 1.50 (0.1–29.2) |
| Tumor size | | | ≤4 cm : >4 cm | 86 : 23 | 80 : 21 |
| Depth of cervix invasion | | | ≤1/2 : >1/2 | 26 : 83 | 27 : 74 |
| Parametrial invasion | | | Negative : Positive | 94 : 15 | 86 : 15 |
| Resection margin involvement | | | Negative : Positive | 85 : 24 | 86 : 15 |
| Lymphovascular invasion | | | Negative : Positive | 55 : 54 | 53 : 48 |
| Pelvic lymph node involvement | | | Negative : Positive | 76 : 33 | 71 : 30 |
| Concurrent chemotherapy | | | No : Yes | 29 : 80 | 31 : 70 |
| External beam radiotherapy | | | No : Yes | 0 : 109 | 8 : 93 | Median (range) (Gy) | 50.4 (25.2–54) | 50.4 (5.4–54) |
| Brachytherapy | | | No : Yes | 24 : 85 | 17 : 84 | Median (range) (Gy) | 21 (7–21) | 21 (7–28) |
|
|